Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meghan Mallett

Nurse Practitioner, Family Conway, AR Nurse Practitioner

NPI 1295193191 CMS profile 10692639

3015 Westover Dr, Conway, AR 72032

Open in the dashboard

General payments

$25,227

98 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meghan Mallett of Conway, AR is reported in the CMS Open Payments database as having received $25,227 across 98 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,756 34
2024 General $7,055 39
2023 General $212 13
2022 General $33 2
2021 General $171 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meghan Mallett
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Meghan Mallett were reported at $17,756. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Meghan Mallett Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $171 $124 $35–$379 $132
2022 $33 $141 $44–$430 $149
2023 $212 $154 $49–$476 $160
2024 $7,055 $165 $51–$504 $164
2025 $17,756 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Insulet Corporation $24,351 47 payments
  2. Abbott Laboratories $123 7 payments
  3. Lilly USA, LLC $113 7 payments
  4. GlaxoSmithKline, LLC. $101 6 payments
  5. Pfizer Inc. $101 5 payments
  6. Novo Nordisk Inc $82 5 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $81 4 payments
  8. AstraZeneca Pharmaceuticals LP $75 5 payments
  9. Dexcom, Inc. $53 3 payments
  10. Amgen Inc. $34 2 payments
  11. Other $114 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,907 33 payments
  2. Food and Beverage $934 55 payments
  3. Travel and Lodging $386 10 payments
Products named General payments · program years 2021–2025
  1. Omnipod $24,351 47 payments
  2. FreeStyle Libre $101 6 payments
  3. TRELEGY ELLIPTA $84 5 payments
  4. ZEPBOUND $69 4 payments
  5. MOUNJARO $69 4 payments
  6. PREVNAR 20 $64 3 payments
  7. COMIRNATY $64 3 payments
  8. PAXLOVID $57 3 payments
  9. RYBELSUS $54 3 payments
  10. Ozempic $54 3 payments
  11. Other $580 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 116 drugs

Part D claims

6,990

Median for Nurse Practitioner: 389

Drug cost

$611,379

Median for Nurse Practitioner: $21,885

Branded share of claims

21.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 163 $187,885
Jardiance Empagliflozin Brand 101 $104,864
Mounjaro Tirzepatide Brand 69 $78,893
Eliquis Apixaban Brand 83 $57,209
Farxiga Dapagliflozin Propanediol Brand 34 $33,248
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $24,076
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 19 $16,137
Trulicity Dulaglutide Brand 12 $14,327
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 34 $11,099
Omnipod Dash Pods (Gen 4) Insulin Pump Cart,cont Inf,bt Brand 11 $6,843

The 10 drugs with the highest cost, of 116 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$83,797

Of which drugs: $4,744

Medicare patients

291

Average age 74

Services billed

2,188

188 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 42%
Diabetes 34%
Ischemic heart disease 24%
Depression 21%
Atrial fibrillation 17%
Heart failure 12%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 15 15 $3,263
Vaccine for influenza for injection into muscle 90653 Office 15 15 $1,191

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $26
$26 — —
Repatha
  • Amgen Inc. $26
$26 — —
NURTEC ODT
  • PFIZER INC. $25
$25 — —
Veozah
  • Astellas Pharma US Inc $25
$25 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $17
$17 36 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record